Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | UGCG | Q16739 | 4/20 | 0.36 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25601641 | 1.00 | CXCR2 (0.44) | CXCR2EGLN1PPIAHDAC6KDM4E | |
| SCHEMBL23460143 | 1.00 | CXCR2 (0.44) | CXCR2EGLN1PPIAHDAC6KDM4E | |
| SCHEMBL25549184 | 0.88 | CXCR2 (0.44) | CXCR2EGLN1PPIAHDAC6KDM4E | |
| SCHEMBL25556280 | 0.88 | CXCR2 (0.44) | CXCR2EGLN1PPIAHDAC6KDM4E | |
| SCHEMBL25601618 | 0.88 | CXCR2 (0.58) | CXCR2KDM4EALDH1A1MAPTMME | |
| SCHEMBL23459904 | 0.88 | CXCR2 (0.58) | CXCR2KDM4EALDH1A1MAPTMME | |
| SCHEMBL25553889 | 0.87 | EGLN1 (0.42) | CXCR2EGLN1PPIAHDAC6KDM4E | |
| SCHEMBL25548999 | 0.87 | EGLN1 (0.42) | CXCR2EGLN1PPIAHDAC6KDM4E | |
| SCHEMBL23459945 | 0.87 | EGLN1 (0.43) | CXCR2EGLN1PPIAHDAC6KDM4E | |
| SCHEMBL23459947 | 0.87 | EGLN1 (0.43) | CXCR2EGLN1PPIAHDAC6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021113808-A1 | CFTR-MODULATING ARYLAMIDES | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, ABCC1 | CXCR2 78/4885EGLN1 2445/4885PPIA 3760/4885 |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885EGLN1 623/4885PPIA 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.